沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病肺气肿患者血清中性粒细胞弹性蛋白酶、α1-抗胰蛋白酶的影响

沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病肺气肿患者血清中性粒细胞弹性蛋白酶、α1-抗胰蛋白酶的影响
孙金林;陈旭东
【期刊名称】《国际医药卫生导报》
【年(卷),期】2014(20)2
【摘要】目的探讨吸入舒利迭(沙美特罗替卡松粉吸入剂)对COPD(慢性阻塞性肺疾病)肺气肿患者血清NE、α 1-AT的影响,为临床COPD肺气肿治疗提供依据.方
法选择COPD肺气肿患者142例,按照COPD严重程度进行分型,轻度75例,中度42例,重度25例,所有患者均采用舒利迭治疗,另选30例健康体检者作对照组,观察三组患者治疗前后血清NE、α 1-AT的变化情况,并与对照组比较;观察患者肺气肿、肺功能恢复情况.结果治疗前不同严重程度患者的α1-AT较健康对照组明显降低(P ＜0.05),病情越严重,α1-AT水平越低(P＜0.05),而NE水平则较健康对照组明显增高,随病情严重度增加而增加(P＜0.05);治疗后轻度COPD患者α1-AT明显增,NE
则明显下降(P＜0.05);中度、重度COPD患者α1-AT及NE改善不明显或无改善(P＞0.05);轻度组患者肺气肿恢复率、肺功能改善明显高于中、重度患者(P＜
0.05).结论舒利迭治疗COPD肺气肿,对病情较轻的患者可有效改善NE、α1-AT
水平,使蛋白酶/抗蛋白酶趋于平衡,但对于中度、重度的患者的效果甚
微.%Objective To investigate the effect of inhaled seretide in serum NE,α1-AT of COPD patients with emphysema,in order to provide basis for clinically treating emphysema.Methods 142 COPD patients with emphysema were selected and parted according to severity of COPD (75 mild cases,42 moderate cases and 25 severe cases),who were all treated
with seretide.30 healthy people were selected as control group.Serum NE,α1-AT levels of three groups of patients before and after treatment and control group,emphysema and lung function recovery of patients were observed.Results Before treatment,α1-AT level of patients was lower than that of control group(P ＜0.05); the more serious illness was,the lower α1-AT level was (P ＜ 0.05).NE level of patients was significantly higher than that of control group; the more serious illness was,the higher NE level was (P ＜ 0.05).After treat ment,α1-AT level of mild patients significantly increased,but NE level significantly decreased (P ＜0.05); α1-AT levels of moderate and severe patients didn' t significantly change (P ＞ 0.05).The emphysema recovery rate and lung function of mild patients improved more than those of moderate and severe patients (P ＜ 0.05).Conclusions Inhaled seretide in the treatment of COPD with emphysema can effectively improve NE and α1-AT level of mild patients,make protease/antiprotease balanced,but has little effect on moderate and severe patients.
【总页数】4页(P193-196)
【作者】孙金林;陈旭东
【作者单位】250000济南,山东省交通医院呼吸内科;250000济南,山东省交通医院呼吸内科
【正文语种】中文
【相关文献】
1.沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病肺气肿患者α1-抗胰蛋白酶的影响[J], 王春生
2.沙美特罗替卡松粉吸入剂联合无创正压通气对慢性阻塞性肺疾病并呼吸衰竭患者营养状况及血清人克拉拉细胞蛋白、肺表面活性物质相关蛋白D水平的影响研究[J], 韦永刚;赵娜
3.噻托溴铵吸入剂与沙美特罗替卡松粉吸入剂联合治疗对中重度慢性阻塞性肺疾病稳定期患者肺功能和生活质量的影响 [J], 韦永刚;付德安
4.茶碱缓释片联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的疗效及对患者肺功能的影响观察 [J], 陈树新; 陈翠环
5.沙美特罗替卡松粉吸入剂对哮喘-慢性阻塞性肺疾病重叠综合征患者肺功能心率变异性及肿瘤坏死因子相关蛋白的影响分析 [J], 席贝贝;武梦佳;余翠果
因版权原因，仅展示原文概要，查看原文内容请购买。